Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - Palobiofarma (Details) |
1 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2019
USD ($)
|
Jun. 30, 2025
USD ($)
|
Jun. 30, 2024
USD ($)
|
Dec. 31, 2024
USD ($)
|
|
| Agreements | ||||
| Payments of consideration under RPAs, AAAs and CPPAs | $ 8,000,000 | $ 37,000,000 | ||
| Long-term royalty and commercial payment receivables under the cost recovery method | 58,937,000 | $ 55,936,000 | ||
| Short-term royalty and commercial payment receivables under the cost recovery method | 700,000 | 413,000 | ||
| Palobiofarma | Royalty Purchase Agreement | ||||
| Agreements | ||||
| Number of drug candidates | 6 | |||
| Payments of consideration under RPAs, AAAs and CPPAs | $ 10,000,000 | |||
| Long-term royalty and commercial payment receivables under the cost recovery method | $ 10,000,000 | |||
| Short-term royalty and commercial payment receivables under the cost recovery method | 0 | |||
| Allowance for credit losses | $ 0 | $ 0 | ||